Becton, Dickinson and Company (NYSE:BDX) Stake Boosted by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 224.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,185 shares of the medical instruments supplier’s stock after purchasing an additional 16,034 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $5,260,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Tompkins Financial Corp grew its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the last quarter. Radnor Capital Management LLC grew its holdings in shares of Becton, Dickinson and Company by 1.7% during the third quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 48 shares during the last quarter. Wesbanco Bank Inc. raised its position in shares of Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock worth $580,000 after purchasing an additional 48 shares during the period. Umpqua Bank lifted its holdings in shares of Becton, Dickinson and Company by 1.8% in the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock worth $660,000 after purchasing an additional 49 shares during the last quarter. Finally, Americana Partners LLC boosted its position in Becton, Dickinson and Company by 3.5% during the 3rd quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier’s stock valued at $354,000 after purchasing an additional 50 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BDX shares. Piper Sandler boosted their price target on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, February 12th. Finally, Barclays lifted their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $278.29.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Bertram L. Scott sold 700 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $227.99, for a total value of $159,593.00. Following the sale, the director now directly owns 36,033 shares in the company, valued at $8,215,163.67. The trade was a 1.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the sale, the executive vice president now owns 14,217 shares of the company’s stock, valued at $3,113,949.51. The trade was a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,544 shares of company stock valued at $2,370,309. 0.36% of the stock is owned by insiders.

Becton, Dickinson and Company Trading Up 1.1 %

Shares of NYSE:BDX opened at $227.56 on Thursday. The company has a 50 day moving average of $232.85 and a 200-day moving average of $233.38. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The firm has a market cap of $65.34 billion, a P/E ratio of 37.80, a P/E/G ratio of 1.61 and a beta of 0.40. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.83%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company declared that its board has authorized a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.